comparemela.com
  1. Home
  2. Live Updates
  3. Versus Soc Alone - Breaking News

Latest Breaking News On - Versus soc alone - Page 2 : comparemela.com

Novartis receives positive CHMP opinion for Pluvicto® for

Phase III VISION trial showed Pluvicto® plus best standard of care significantly improved survival for patients with pre-treated PSMA-positive mCRPC1 .

United statesFrance generalKarim fizaziGustave roussyEuropean commissionWorld health organizationInternational prospectiveExchange commissionInnovative medicines internationalNovartis pharmaceuticalsUs national library of medicineEuropean medicines agencyCommittee for medicinal products human useMedicinal productsHuman useMedical oncology

Novartis Pharma AG: Novartis receives positive CHMP opinion for Pluvicto for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer

Phase III VISION trial showed Pluvicto plus best standard of care significantly improved survival for patients with pre-treated PSMA-positive mCRPC1 Approximately 473,000 prostate cancer cases and

France generalUnited statesIsabella zinckKarim fizaziFran rodriguesNicole zinsli sommSamir shahParag mahantiJulie masowSloan simpsonGustave roussyAlina levchukEuropean commissionWorld health organizationInternational communicationsNovartis us external communications

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.